Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30263258 | 1.00 | ADRA2A (0.39) | ADRA2AADRA2BADRA2CADRA1AIDO1 | |
| SCHEMBL20725128 | 0.82 | ADRA2A (0.43) | ADRA2AADRA2BADRA2CADRA1AIDO1 | |
| SCHEMBL28011816 | 0.74 | IDO1 (0.44) | ADRA2AADRA2BADRA2CADRA1AIDO1 | |
| SCHEMBL145977 | 0.74 | IDO1 (0.57) | ADRA2AADRA1AIDO1 | |
| SCHEMBL29357487 | 0.74 | IDO1 (0.57) | ADRA2AADRA1AIDO1 | |
| Hydrochloric Acid SCHEMBL6542205 | 0.73 | IDO1 (0.45) | ADRA2AADRA2BADRA2CADRA1AIDO1 | |
| SCHEMBL7317272 | 0.71 | ESR1 (0.47) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL10682685 | 0.71 | ESR1 (0.51) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL9391610 | 0.71 | ESR1 (0.47) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL6784204 | 0.70 | IDO1 (0.53) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085048-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | EPIVARIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12441689-B2 | ACSS2 inhibitors and methods of use thereof | EPIVARIO, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-3710430-B9 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2024-10-30 | — | — | EP | disclosed |
| EP-3710430-B1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2024-07-03 | — | — | EP | disclosed |
| US-20230212131-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230174507-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2023-06-08 | — | — | US | disclosed |
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230116201-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-04-13 | — | — | US | disclosed |
| EP-4149928-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | Metabomed Ltd (IL) | 2023-03-22 | — | — | EP | disclosed |
| US-20230084752-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2023-03-16 | — | — | US | disclosed |
| EP-4097084-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | Anima Biotech Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-3969439-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | Metabomed Ltd (IL) | 2022-03-23 | — | — | EP | disclosed |
| WO-2021216665-A9 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021229571-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021216665-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021154902-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| US-10851064-B2 | ACSS2 inhibitors and methods of use thereof | METABOMED LTD. (IL) | 2020-12-01 | — | — | US | disclosed |
| WO-2020230134-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2020-11-19 | — | — | WO | disclosed |
| EP-3710430-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | Metabomed Ltd (IL) | 2020-09-23 | — | — | EP | disclosed |
| US-20190263758-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | COL1A1, COL2A1, COL14A1 | ADRA2A 4548/4885ADRA2B 4288/4885ADRA2C 4636/4885 |
| US-20230174507-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, ADSS2, GLS2 | ADRA2A 4006/4885ADRA2B 2373/4885ADRA2C 3378/4885 |
| US-20230212131-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | COL1A1, COL2A1, COL14A1 | ADRA2A 4555/4885ADRA2B 4304/4885ADRA2C 4641/4885 |
| US-20230084752-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, ADSS2, GLS2 | ADRA2A 3601/4885ADRA2B 2300/4885ADRA2C 3526/4885 |
| US-10851064-B2 | ACSS2 inhibitors and methods of use thereof | ACSS2, GLS2, ADSS2 | ADRA2A 3471/4885ADRA2B 2185/4885ADRA2C 3379/4885 |
| US-20190263758-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ADSS2 | ADRA2A 3471/4885ADRA2B 2185/4885ADRA2C 3379/4885 |
| US-20260085048-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ACSL3 | ADRA2A 2305/4885ADRA2B 1548/4885ADRA2C 2008/4885 |
| US-20230116201-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | COL1A1, COL2A1, COL14A1 | ADRA2A 4555/4885ADRA2B 4304/4885ADRA2C 4641/4885 |
| US-12441689-B2 | ACSS2 inhibitors and methods of use thereof | ACSS2, ADSS2, GLS2 | ADRA2A 3601/4885ADRA2B 2300/4885ADRA2C 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.